Emerging Data on Iron Management: Clinical Implications

ASN Renal Week, October, 2004

Welcome, Introduction and Program Overview

Allen R. Nissenson, MD
Please make sure that all slide images load before starting the lecture

Windows Media Player
Option 1 Streaming Server
Option 2 For slow connections, right click on preload icon and choose "save target as". Play file from saved location.

Real Audio Player
Option 3 Streaming, Firewall-friendly
Option 4 Preload (2-5 mB)

Audio FAQ
For problems and suggestions, please click on this link.
This group of talks is accredited for 1.5 CME Category 1 credits for physicians by the American Society of Nephrology. This group of talks has a single post-test, which must be completed along with an evaluation form to obtain continuing education credit.
Date of Web Release: January, 2005
CME Category 1 Credit Eligible Through: March 1, 2006
CME Category 1 Credits/Completion Time: 1.5
Target Audience: Practicing nephrologists and internists.
Method of participation: Listen to the talk(s), read the PubMed abstracts of linked slides and references, take the post-test, read the abstracts linked to in the post-test feedback section.
This official symposium was sponsored by a restricted educational grant from Watson Pharma, Inc.
The educational objectives for this talk are presented on the conference page. To view the objectives, click here.

Dr. Allen R. Nissenson:
No disclosed off-label use.

Accreditation Statement
The American Society of Nephrology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The ASN designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

The American Medical Association has determined that non-US licensed physicians who participate in this CME activity are eligible for AMA PRA category 1 credit.

Additional CME policy statements of the ASN, which is the accrediting organization for this talk, are given in detail on the ASN Renal Week Home Page, including Disclaimer and User Instructions.

The CME policy statements of HDCN are listed on this page.

Dr. Allen R. Nissenson:
I had a series of about 4 or 5 slides to show you to introduce the topic, which apparently did not make into the slide package since Dr. Coyne's slides are up there, but I will give you just this brief introduction, which is to say that there are a whole variety of issues that are currently unresolved regarding iron. Clearly, when we first decided to do this, it was sort of hard to think about what is new and unique in iron therapy, but it turns out there are a still a lot of important unanswered questions related to iron, and we can only handle a small number of these.

We thought we would focus on, First, a presentation by Dr. Coyne who is going to discuss current data on IV iron therapy and the appropriate use of IV iron in this population, then presentation by Brad Warady on the use of parenteral irons in pediatric patients, which is an area that is increasingly important with the growing population of pediatric patients on hemodialysis.Thirdly, we will have a presentation by Dr. Kalantar-Zadeh on the relationship between iron stores and morbidity, and some very interesting data in that regard.

Then finally I am going to close the formal part of the program talking about assessment of iron stores, some information you are already familiar with the pluses and minuses of TSAT and ferritin, but then going to some other information about newer tests of iron status, where that stands, where we might go with this in the future, and then we will try to leave a few minutes for questions and answers.

I prefer to have the questions and answers at the end for the panel rather than after each talk.